Pelthos Therapeutics
PTHS
14 hedge funds and large institutions have $13M invested in Pelthos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.
6,818% more capital invested
Capital invested by funds: $187K → $13M (+$12.8M)
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
180% more funds holding
Funds holding: 5 → 14 (+9)
14.98% more ownership
Funds ownership: 0.23% → 15.21% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$6.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.62M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.52M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$516K |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$255K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$172K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
M
1
Murchinson
Toronto,
Ontario, Canada
| $7.84M | +$6.8M | +280,000 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $1.87M | +$1.62M | +66,836 | New |
|
|
IC
3
Ikarian Capital
Dallas,
Texas
| $1.75M | +$1.52M | +62,451 | New |
|
|
BFM
4
Boothbay Fund Management
New York
| $595K | +$516K | +21,245 | New |
|
|
DP
5
Diadema Partners
Morristown,
New Jersey
| $294K | +$255K | +10,498 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $289K | +$225K | +9,286 | +889% |
|
|
DMKJ
7
David M. Knott Jr
| $171K | +$148K | +6,112 | New |
|
|
PAP
8
Persistent Asset Partners
Hong Kong
| $67.3K | +$58.3K | +2,403 | New |
|
|
SPIA
9
Steward Partners Investment Advisory
New York
| $53.5K | +$46.4K | +1,910 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $23.2K | +$19.9K | +818 | +9,089% |
|
11
UBS Group
Zurich,
Switzerland
| $3.84K | +$1.75K | +72 | +111% |
|
12
Bank of America
Charlotte,
North Carolina
| $308 | +$218 | +9 | +450% |
|
13
Citigroup
New York
| $28 | +$24 | +1 | New |
|
14
JP Morgan Chase
New York
| $28 | +$24 | +1 | New |
|
|
15
Millennium Management
New York
| – | -$172K | -13,671 | Closed |
|
PTHS Hedge Fund Activity: Q3 2025 in Review
14 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q3 2025, worth a combined $13M — up 6,818% from $187K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PTHS positions and 1 closed out — a net gain of 9 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Murchinson, opening a new position worth an estimated $6.8M. The largest seller was Millennium Management, exiting entirely with an estimated $172K sold.
- 14 institutional investors held Pelthos Therapeutics (PTHS) as of Q3 2025, up from 5 in Q2 2025.
- Funds reported $13M of Pelthos Therapeutics stock for Q3 2025, up 6,818% quarter-over-quarter.
- 10 funds opened new Pelthos Therapeutics positions in Q3 2025 and 1 closed out, a net change of +9 holders.
- The largest Pelthos Therapeutics buyer in Q3 2025 was Murchinson, an estimated $6.8M added.
- The largest Pelthos Therapeutics seller in Q3 2025 was Millennium Management, an estimated $172K sold.
Based on aggregated 13F filings for Q3 2025.